Aehr Test Systems (NASDAQ: AEHR) stock jumps 20% as record backlog fuels growth outlook

Aehr Test Systems, Inc. (NASDAQ: AEHR) shares surged 20.33% to US$93.08 during the July 21 market session, gaining US$15.72 from the previous close as investors returned to the semiconductor test-equipment company’s record order backlog and ambitious growth outlook. The move extended the volatile revaluation that began after Aehr reported US$60.7 million of quarterly bookings, a US$100.6 million effective backlog and fiscal 2027 revenue guidance of US$130 million to US$150 million. The July 21 rally values Aehr at approximately US$3 billion on a basic-share basis, even though the company generated US$50 million of revenue during fiscal 2026. The central question is whether artificial-intelligence processors, silicon photonics and recovering power-semiconductor demand can convert the backlog into enough revenue, earnings and cash flow to support that expanded valuation.

Why is Aehr Test Systems stock surging again during the July 21 market session?

The July 21 advance represents a sharp reversal from the previous three sessions. AEHR closed at US$87.79 on July 15 after its first post-earnings surge, before declining to US$84.20 on July 16, US$81.05 on July 17 and US$77.36 on July 20. The July 21 snapshot at US$93.08 therefore placed the stock above its first post-results close while remaining below the US$110.20 intraday high reached on July 15.

Measured from the July 14 close of US$72.01, the stock had gained approximately 29.3% by the July 21 snapshot. It nevertheless remained about 17.9% below its June 22 close of US$113.33. AEHR’s published 52-week range extends from US$14.72 to US$126.62, leaving the shares roughly 26.5% below the high but more than six times the low.

The move should be described as a continuation of the post-earnings revaluation rather than attributed to an unconfirmed new event. Aehr’s latest major financial announcement remains its July 14 results and outlook, which materially changed expectations for the coming financial year. The company’s current guidance implies that fiscal 2027 revenue could reach between 2.6 and three times the fiscal 2026 level.

The market is therefore attempting to price a business that could look dramatically different within 12 months. That creates considerable upside sensitivity when new orders support the guidance, but it also creates sharp downside sensitivity if shipments, customer qualifications or production ramps are delayed.

What does Aehr Test Systems sell, and why is semiconductor burn-in gaining value?

Aehr supplies systems used to test, burn in and stabilise semiconductor devices before they are installed in vehicles, data centres, telecommunications equipment and other expensive applications. Burn-in places devices under controlled electrical and thermal stress to identify early failures that might otherwise emerge after deployment.

The company’s FOX product family supports testing at the wafer, singulated-die and module levels. Its FOX-XP and FOX-NP systems can test multiple wafers or carriers in parallel, while proprietary WaferPak contactors connect customer devices to the test system. Aehr also sells automatic wafer aligners, DiePak carriers and loaders, creating additional equipment and consumables revenue around each installed platform.

Aehr’s exposure expanded through the acquisition of Incal Technology, Inc., which added the Sonoma and Tahoe package-level burn-in systems. Sonoma is designed for high-power artificial-intelligence accelerators, graphics-processing units and high-performance computing processors. This gives Aehr products on both sides of the semiconductor packaging process, with FOX systems addressing wafer-level screening and Sonoma addressing completed packaged devices.

The commercial argument is straightforward. Advanced processors are becoming more powerful, expensive and difficult to cool, while artificial-intelligence infrastructure operators cannot easily tolerate failures after installation. Testing a processor before it enters a costly server or accelerator platform may therefore become more valuable as the device itself becomes more complex.

Aehr also benefits when customers move burn-in earlier in the manufacturing process. Detecting a defective device at wafer level can prevent customers from spending additional money packaging and integrating a chip that later fails. The economic value comes from reducing downstream yield loss rather than merely adding another test step.

Can Aehr convert its US$100.6 million effective backlog into fiscal 2027 revenue?

Aehr ended May 29 with a formal backlog of US$80.6 million. Orders received after the year-end increased the effective backlog to US$100.6 million, more than twice the US$50 million of revenue generated during fiscal 2026. Fourth-quarter bookings reached a company record of US$60.7 million.

Management expects fiscal 2027 revenue of US$130 million to US$150 million, representing year-on-year growth of approximately 160% to 200%. The effective backlog covers about 67% of the upper end of guidance and approximately 77% of the lower end, giving Aehr substantially greater visibility than it had entering fiscal 2026.

The backlog is important, but it is not identical to recognised revenue. Aehr must manufacture the systems and contactors, complete customer-specific configurations, deliver the equipment and satisfy applicable acceptance requirements. Revenue timing can therefore shift when customers alter production schedules or qualification programmes.

Fourth-quarter results offered encouraging evidence that conversion had begun. Revenue increased 33% to US$18.8 million from US$14.1 million a year earlier. Generally accepted accounting principles net income improved to US$1.4 million, or US$0.04 per diluted share, from a US$2.9 million loss. Adjusted net income reached US$3.6 million, or US$0.11 per share, compared with an adjusted loss of US$0.2 million.

The full-year numbers remained less impressive because the major bookings arrived late in the period. Fiscal 2026 revenue declined to US$50 million from US$59 million, while the generally accepted accounting principles net loss widened to US$7.1 million. Adjusted net income fell to US$0.9 million from US$4.6 million, and operating activities used US$3.3 million of cash.

Aehr is consequently moving from a weak reported year into what management expects to be an exceptional growth year. The thesis depends on the speed and profitability of that transition rather than the backlog figure by itself.

How diversified is Aehr’s growth across artificial intelligence, photonics and power chips?

Artificial intelligence currently provides the strongest growth narrative. Aehr said its lead artificial-intelligence production customer is significantly increasing capacity and moving burn-in for training and inference accelerators from system-level testing to wafer-level screening. That shift can increase demand for FOX systems and proprietary WaferPak contactors as production volumes expand.

Aehr has also completed benchmark testing with another major supplier of artificial-intelligence accelerators, central processing units and network processors. The prospective customer expressed interest in progressing to pilot-production validation for an existing high-volume processor and requested an evaluation of a second device. These engagements are promising, but they remain evaluation-stage opportunities until Aehr announces firm production orders.

Package-level artificial-intelligence testing is developing through the Sonoma platform. Aehr reported follow-on production demand from its lead hyperscale customer and said the customer was forecasting a substantial expansion of Sonoma purchases for a second device requiring twice the power per package of the first programme. Aehr is also pursuing package-level testing opportunities involving application-specific integrated circuits, network processors, automotive edge computing and robotics.

Silicon photonics provides a second data-centre growth lane. These devices help move enormous volumes of information within and between artificial-intelligence computing clusters. Aehr received a follow-on order from its lead silicon photonics customer for an automated FOX-XP system capable of testing as many as nine 300-millimetre wafers in parallel. The equipment will support production burn-in for optical interconnect devices used in hyperscale data centres.

Power semiconductors offer a possible cyclical recovery. Aehr announced approximately US$8 million of recent silicon carbide WaferPak orders, including expanded production orders from its lead silicon carbide customer and an order from a major automotive company evaluating devices for a new generation of electric vehicles. Management also expects renewed demand for gallium nitride testing as artificial-intelligence data centres require more efficient power conversion.

The diversification is strategically valuable because Aehr had previously depended heavily on silicon carbide demand linked to electric vehicles. Artificial intelligence processors, package-level testing and silicon photonics can reduce that dependence. However, much of the growth still comes through a relatively small number of large customer programmes.

Does Aehr’s stronger cash position offset customer concentration and execution risk?

Aehr ended fiscal 2026 with US$116.5 million of cash, cash equivalents and restricted cash, up from US$37.1 million at the end of the third quarter. The increase was supported by a US$60 million at-the-market equity programme completed in April.

The financing materially strengthened Aehr’s ability to purchase inventory, increase production capacity, support customer installations and fund working capital during the expected revenue ramp. It also increased the outstanding share count, meaning future growth must be assessed on a per-share basis rather than through revenue alone.

Customer concentration remains one of the principal operating risks. In fiscal 2025, Aehr’s five largest customers accounted for approximately 77% of revenue, with two customers contributing about 39% and 15%. The current backlog appears more diversified by application, but the company continues to refer to lead artificial-intelligence, hyperscale, silicon photonics and silicon carbide customers whose order timing could materially affect quarterly results.

Large equipment orders can be uneven. A customer may buy several systems during an initial manufacturing expansion and then pause until another factory, device generation or production line requires capacity. Aehr’s proprietary contactors and consumables may provide recurring revenue around the installed base, but they do not completely eliminate equipment-cycle volatility.

The balance sheet provides Aehr with greater room to manage these fluctuations. It does not remove the operational requirement to deliver systems, complete customer qualifications and turn forecast demand into firm purchase orders.

What valuation is the July 21 share price assigning to Aehr’s fiscal 2027 guidance?

At US$93.08 and using roughly 32 million basic shares after the completed equity programme, Aehr’s market capitalisation is approximately US$3 billion. That represents around 60 times fiscal 2026 revenue and approximately 20 to 23 times management’s fiscal 2027 revenue guidance. The calculation is an analytical estimate based on the intraday price snapshot and the company’s recent post-offering share count.

Management expects adjusted net income to equal 18% to 22% of fiscal 2027 revenue. Applying those margins to the guidance boundaries produces an implied adjusted net-income range of approximately US$23 million to US$33 million. The July 21 market capitalisation therefore represents roughly 90 to 130 times that implied range before adjusting for Aehr’s cash position.

Those multiples show that the market is not merely pricing backlog conversion. Investors are assigning substantial value to growth continuing beyond fiscal 2027, additional artificial-intelligence customers entering production, silicon photonics becoming a large market and semiconductor manufacturers adopting more wafer-level and package-level burn-in.

The optimistic case is that Aehr owns differentiated technology addressing increasingly expensive and power-intensive devices. A customer qualification can produce system orders, WaferPak demand, capacity additions and recurring consumables revenue over several product generations.

The cautious case is that the July 21 price already discounts much of the successful-execution scenario. Delayed shipments, weaker margins or a slower order pipeline could therefore produce disproportionate volatility even when the longer-term market opportunity remains intact.

Which measurable milestones would strengthen or weaken the Aehr Test Systems thesis?

The most important milestone is the conversion of effective backlog into quarterly revenue. Fiscal 2027 revenue must move rapidly towards the US$130 million to US$150 million range without requiring repeated reductions or delays in guidance.

A second milestone is adjusted profitability. Management’s 18% to 22% net-income target would represent a major improvement from fiscal 2026. Investors will need evidence that higher production volumes create operating leverage after manufacturing costs, research spending, stock-based compensation and acquisition-related expenses.

New customer qualifications could strengthen the thesis materially. Progress by the second major artificial-intelligence processor supplier from benchmarking into pilot production would reduce dependence on the current lead programme. Additional silicon photonics systems and Sonoma orders would provide similar evidence that Aehr is building repeatable platforms rather than relying on isolated equipment purchases.

The thesis would weaken if the effective backlog failed to convert within the anticipated period, customers delayed manufacturing ramps or Aehr’s gross and operating margins did not improve alongside revenue. Dependence on a limited number of customers could magnify any such delay.

Aehr has entered fiscal 2027 with stronger commercial evidence than it possessed one year earlier. Record bookings, a large backlog, a strengthened balance sheet and exposure to several high-growth semiconductor markets support the operating case.

The unresolved issue is valuation. At approximately US$93 during July 21 trading, the market is already pricing a large part of management’s growth forecast and expecting additional opportunities beyond it. The next stage of the Aehr Test Systems story must therefore be measured in delivered systems, recognised revenue, expanding margins and additional production customers rather than another increase in prospective opportunity.

What are the key takeaways from Aehr Test Systems’ July 21 rally and backlog?

• Aehr Test Systems shares surged 20.33% to US$93.08 during the July 21 market session.
• The stock was approximately 29% above its July 14 close but remained nearly 18% below its June 22 close.
• Aehr reported record quarterly bookings of US$60.7 million and an effective backlog of US$100.6 million.
• Management expects fiscal 2027 revenue of US$130 million to US$150 million, representing growth of approximately 160% to 200%.
• Artificial-intelligence processors, silicon photonics and recovering silicon carbide orders are supporting the growth outlook.
• Aehr ended fiscal 2026 with US$116.5 million in cash and restricted cash after completing a US$60 million equity programme.
• The next proof points are backlog conversion, adjusted profitability, additional production customers and sustained growth beyond fiscal 2027.